<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Kidney transplantation in adults: Management of the patient with a failed kidney transplant</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Kidney transplantation in adults: Management of the patient with a failed kidney transplant</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Kidney transplantation in adults: Management of the patient with a failed kidney transplant</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Brent W Miller, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Daniel C Brennan, MD, FACP</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John Vella, MD, FACP, FRCP, FASN, FAST</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Albert Q Lam, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 21, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Over the last few decades, the long-term survival of kidney allografts has significantly increased. Median survival has increased from 8.2 to 11.7 years for deceased donor transplants and from 12.1 to 19.2 years for living donor transplants over the last 20 years [<a href="#rid1">1</a>]. Despite this success, a substantial number of kidney transplant recipients eventually require the permanent reinstitution of kidney replacement therapy because of allograft failure. As an example, in 2018, approximately 11 percent of new patients added to the kidney transplant waiting list had a previous transplant [<a href="#rid2">2-4</a>]. In addition, among kidney transplants performed between 2013 and 2018, 1.1 percent of the prevalent kidney transplant recipients returned to dialysis therapy in 2018 alone [<a href="#rid2">2</a>].</p><p>The survival of such patients on dialysis appears to be relatively poor [<a href="#rid5">5-8</a>]. In a study of 4743 kidney transplant recipients in Canada, for example, the risk of death was significantly higher with allograft failure versus those with continued allograft function (adjusted hazard ratio [HR] 3.4, 95% CI 2.75-4.2) [<a href="#rid7">7</a>].</p><p>This topic will review the medical and surgical management of patients with a failed kidney transplant. A discussion of risk factors for graft failure in kidney transplantation is presented elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7302.html" rel="external">"Kidney transplantation in adults: Risk factors for graft failure"</a>.)</p><p class="headingAnchor" id="H1835789847"><span class="h1">MANAGEMENT OF IMMUNOSUPPRESSION</span><span class="headingEndMark"> — </span>One of the most important aspects of managing the patient with a failing kidney allograft is deciding when and how to safely stop maintenance immunosuppressive therapy. In general, the primary goal is to withdraw the immunosuppressive agents without precipitating rejection, causing any adverse effects related to drug withdrawal, or exacerbating allosensitization. Secondarily, the impact of sensitization should be considered for those patients pursuing another transplant. Continuation of immunosuppression might be necessary in patients who are felt to be too frail to tolerate a transplant nephrectomy, which is a major operation (see <a class="local">'Transplant nephrectomy'</a> below). Our approach to withdrawing immunosuppression and a discussion of the relative benefits and risks of withdrawal are presented below.</p><p class="headingAnchor" id="H4187458903"><span class="h2">Reasons for withdrawal of immunosuppression</span><span class="headingEndMark"> — </span>The most compelling reason to withdraw immunosuppressive medications in dialysis patients with a failed kidney transplant is the increased risk of infection, malignancy, and complications associated with long-term immunosuppression use. Infection is the second leading cause of death in this setting [<a href="#rid9">9</a>]. The dosing of some immunosuppressive agents may be challenging in patients with kidney failure, and there are costs of continued immunosuppression:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Increased risk of infection</strong> – An increased risk of serious infections is observed in both transplant recipients (because of the direct effects of immunosuppressive medications) and dialysis patients (because of immune system derangements from uremia and access-related problems). These factors contribute to the remarkably high incidence of infection in dialysis patients who continue to receive immunosuppressive medications after a kidney allograft has failed. This is particularly concerning in the failed transplant patient utilizing a venous catheter on hemodialysis [<a href="#rid10">10-13</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a retrospective review of 197 patients returning to dialysis, the risk of infection was significantly increased in patients remaining on low-dose immunosuppression, compared with those in whom immunosuppression was withdrawn (1.7 versus 0.5 infections/patient-year, respectively) [<a href="#rid11">11</a>]. Mortality and cardiovascular disease (odds ratios of 3.4 and 4.9) were also increased in the group on immunosuppression. Overall, the nephrectomy rate was 55 percent.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Similar results were noted in a second retrospective review of a long- versus short-taper protocol: More infections occurred in the long-taper group (0.87 versus 0.72 infections/patient-year) [<a href="#rid12">12</a>]. Most infections were dialysis related.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Increased risk of malignancy</strong> – An increased risk of malignancy may occur in patients exposed to immunosuppression and is decreased by immunosuppression withdrawal [<a href="#rid14">14</a>]. This was suggested by a retrospective cohort study consisting of over 8000 first-transplant recipients in the Australia and New Zealand Dialysis and Transplantation Registry [<a href="#rid15">15</a>]. Although the incidence of cancers after allograft failure in kidney transplant recipients was highly variable, the incidence of Kaposi sarcoma and non-Hodgkin lymphoma decreased markedly on reinstitution of dialysis, as did the incidence of lip cancer and melanoma. The decreased risk was generally observed for cancers associated with viral associations such as Kaposi sarcoma, which is associated with human herpes type 8, and non-Hodgkin lymphoma, which is associated with Epstein-Barr virus. The decreased risk of lip cancer may have been due to the association of human papillomavirus and skin cancers. Although melanoma has no known infectious etiology, a causal relationship between immunosuppression and its development in recipients of kidney transplants has been suggested [<a href="#rid16">16</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Complications of glucocorticoid therapy</strong> – Patients on long-term glucocorticoid therapy are at risk for infectious as well as noninfectious complications, including osteoporosis, muscle wasting, cataracts, and hyperglycemia (see  <a class="medical medical_review" href="/z/d/html/7988.html" rel="external">"Major adverse effects of systemic glucocorticoids"</a>). These are important issues given the long current waiting period in the United States for another deceased-donor kidney allograft.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Altered drug dosing</strong> – Several of the standard immunosuppressive agents have special considerations in patients with severe kidney function impairment. As an example, although calcineurin inhibitors (<a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> and <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a>) are not metabolized or excreted by the kidney, their neurotoxicity may compound the neurologic effects of uremia [<a href="#rid17">17</a>]. In addition, kidney failure can result in changes in the pharmacokinetics of <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a>, which may result in higher blood levels of active drug. (See  <a class="medical medical_review" href="/z/d/html/7356.html" rel="external">"Kidney transplantation in adults: Maintenance immunosuppressive therapy"</a>.)</p><p></p><p class="headingAnchor" id="H1520196652"><span class="h2">Approach to withdrawal of immunosuppression</span><span class="headingEndMark"> — </span>There is no high-quality evidence to guide the optimal method for tapering/withdrawing immunosuppression following kidney allograft failure. Most transplant centers have center-specific protocols [<a href="#rid8">8,18</a>]. Our approach (<a class="graphic graphic_algorithm graphicRef121542" href="/z/d/graphic/121542.html" rel="external">algorithm 1</a>), which has resulted in a stable nephrectomy rate of approximately 30 percent, is largely consistent with recommendations of the British Transplantation Society Guidelines and other reviews [<a href="#rid19">19-21</a>]. (See <a class="local">'Transplant nephrectomy'</a> below.)</p><p class="headingAnchor" id="H2595807251"><span class="h3">Early graft failure (&lt;1 year posttransplant)</span><span class="headingEndMark"> — </span>In patients with kidney allograft failure that occurs less than one year after transplant surgery (early allograft failure), we and most transplant centers have adopted a policy of preemptive nephrectomy and immediate withdrawal of immunosuppression at the time of nephrectomy. The rationale for this is the near certainty of an immunologic event with the discontinuation of immunosuppression with an allograft in place and to decrease the risk of infection and malignancy by eliminating continued immunosuppression. In patients who have been taking <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> for longer than three months, we typically taper the prednisone to avoid the development of secondary adrenal insufficiency. Although remnant kidney and ureter may potentially lead to human leukocyte antigen (HLA) sensitization, this theoretical risk is likely to be much lower than the risks of continued immunosuppression after nephrectomy. (See <a class="local">'Indications for nephrectomy'</a> below.)</p><p class="headingAnchor" id="H3033056621"><span class="h3">Late graft failure (&gt;1 year posttransplant)</span><span class="headingEndMark"> — </span>In patients with later (after the first posttransplant year) allograft failure, our approach differs depending upon whether or not the patient is likely to receive another kidney transplant within one year.</p><p class="headingAnchor" id="H348380239"><span class="h4">Planned retransplantation within 1 year</span><span class="headingEndMark"> — </span>For most patients with late graft failure who have a well-defined plan for retransplantation within a year of starting kidney replacement therapy, we adjust immunosuppression as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>We withdraw the antimetabolite (<a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil/sodium or <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">azathioprine</a>) immediately.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We reduce the calcineurin inhibitor (<a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> or <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a>) dose to once daily in the morning. For patients taking tacrolimus, we target a 24-hour trough level of 2 to 5 ng/mL; for those on cyclosporine, we target a 24-hour trough level of 50 to 75 ng/mL. We continue the calcineurin inhibitor at this dose until the time of retransplantation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We continue <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> at 5 mg/day until the time of retransplantation.</p><p></p><p>The rationale to not continue triple immunosuppression in these patients is that it has been associated with higher rates of infection and increased mortality (see <a class="local">'Reasons for withdrawal of immunosuppression'</a> above). In patients receiving <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil/sodium as part of their immunosuppression regimen, the increased risk of infection and death may be related to changes in the pharmacokinetics of mycophenolate with kidney failure, which may result in higher blood levels of active drug. Withdrawal of the calcineurin inhibitor has been associated with an increased risk of sensitization after graft failure and should be avoided if possible. (See <a class="local">'Sensitization'</a> below.)</p><p class="headingAnchor" id="H1461447182"><span class="h4">No planned retransplantation within 1 year</span><span class="headingEndMark"> — </span>In patients who do not have a well-defined plan for retransplantation within a year of starting kidney replacement therapy, our approach depends upon the residual kidney function of the patient. Kidney allograft function tends to deteriorate rapidly after withdrawal of immunosuppression in dialysis patients. Thus, in patients who continue to have good urine output, a longer taper of immunosuppression may help to maintain some kidney allograft function while on dialysis (see <a class="local">'Loss of residual kidney function'</a> below):</p><p class="bulletIndent1"><span class="glyph">●</span>We withdraw the antimetabolite (<a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> or <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">azathioprine</a>) immediately.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We reduce the calcineurin inhibitor (<a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> or <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a>) dose to once daily in the morning. For patients taking tacrolimus, we initially target a 24-hour trough level of 2 to 5 ng/mL; for those on cyclosporine, we initially target a 24-hour trough level of 50 to 75 ng/mL. Subsequent tapering is as follows:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In patients who continue to produce urine (urine output ≥400 mL/day) after allograft failure, we taper the dose of the calcineurin inhibitor slowly, typically over 6 to 12 months until the drug is discontinued. However, the duration of the taper should be adjusted based upon reevaluation of the patient's residual kidney function.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In patients who are oliguric (urine output &lt;400 mL/day) after allograft failure, we generally taper the dose over three to six months until the drug is discontinued. However, if the patient is frail and unlikely to tolerate an urgent transplant nephrectomy if needed within the next few months, we defer tapering the calcineurin inhibitor until the patient's overall physical condition improves. This avoids the risk of precipitating immediate rejection.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We taper <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> by 1 mg/month until the drug is discontinued. If the patient is starting with a maintenance dose of prednisone that is greater than 5 mg/day, we immediately reduce the dose to 5 mg/day and then taper by 1 mg/month until the drug is discontinued.</p><p></p><p class="headingAnchor" id="H1272969640"><span class="h2">Monitoring during withdrawal of immunosuppression</span><span class="headingEndMark"> — </span>All patients who are undergoing withdrawal of their immunosuppression should be closely monitored for complications of withdrawal, including rejection and secondary adrenal insufficiency. Observation for symptoms of rejection (eg, fever, graft pain and/or tenderness, oliguria) requires over a year in most patients, and the signs may be subtle and often missed. (See <a class="local">'Complications of withdrawal'</a> below.)</p><p>In general, patients with failed transplants on dialysis are primarily seen by the nephrologists at their dialysis units according to the routine outpatient schedule and are typically referred back to their transplant program if and when they experience symptomatic rejection. However, some transplant centers continue to follow their patients with failed transplants on a yearly basis if they remain on immunosuppression and have ongoing immunosuppression management requirements. (See <a class="local">'Rejection'</a> below.)</p><p class="headingAnchor" id="H3340260305"><span class="h2">Complications of withdrawal</span><span class="headingEndMark"> — </span>The continued administration of immunosuppressive medications to patients with kidney allograft failure would, at first glance, appear to be unnecessary since such agents increase the risk of infection without providing obvious benefits. However, the withdrawal of immunosuppression may be associated with significant complications:</p><p class="bulletIndent1"><span class="glyph">●</span>Precipitation of rejection possibly requiring transplant nephrectomy</p><p class="bulletIndent1"><span class="glyph">●</span>Secondary adrenal insufficiency</p><p class="bulletIndent1"><span class="glyph">●</span>Loss of residual kidney function</p><p class="bulletIndent1"><span class="glyph">●</span>Potentially adverse immunologic effects among those pursuing another transplantation</p><p class="bulletIndent1"><span class="glyph">●</span>Worsening anemia due to erythropoiesis-stimulating agent (ESA) resistance [<a href="#rid22">22</a>]</p><p></p><p class="headingAnchor" id="H1764947067"><span class="h3">Rejection</span><span class="headingEndMark"> — </span>A major effect of withdrawing immunosuppressive therapy is the possible precipitation of rejection, an event that may require allograft removal (<a class="graphic graphic_diagnosticimage graphicRef58383" href="/z/d/graphic/58383.html" rel="external">image 1</a>). Although transplant nephrectomy is relatively safe, with the main complication being bleeding and a need for transfusion, the addition of another major event at the same time of reinitiation of dialysis may be undesirable. (See <a class="local">'Indications for nephrectomy'</a> below.)</p><p>In patients who develop rejection during withdrawal of immunosuppression, we and others administer a five- to seven-day course of <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> at a dose of 0.3 to 1.0 mg/kg per day; patients are subsequently referred for nephrectomy. Some centers will attempt embolization of the allograft prior to or in preparation for the nephrectomy. By comparison, some nephrologists advocate immediate nephrectomy for those with even mild symptoms of rejection after immunosuppressive agent withdrawal.</p><p>Studies examining patients treated in the calcineurin inhibitor era, beginning with <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> in the 1980s and continuing to today, report an incidence of required transplant nephrectomy ranging from 20 to 65 percent after resuming dialysis [<a href="#rid11">11,12,23-28</a>]. The use of calcineurin inhibitors has been associated with a dramatic increase in the incidence of required transplant nephrectomies after the withdrawal of immunosuppressive agents compared with the prior era of transplantation from the 1960s to 1980s. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>A retrospective review of one center's experience reported an incidence of 4 percent (2 of 46 patients) of required nephrectomy for patients administered <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">azathioprine</a> and <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> versus 21 percent (13 of 62) for those treated with a regimen that included <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> [<a href="#rid12">12</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A second center found that nephrectomy was required in 63 percent (19 of 30) of patients treated with <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a>, <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">azathioprine</a>, and <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> versus 27 percent (4 of 11) of those administered azathioprine and prednisone [<a href="#rid23">23</a>].</p><p></p><p>The reason for the possible association of graft nephrectomy with <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> use is unclear. A potential mechanism is the effect of calcineurin inhibition upon immunologic tolerance [<a href="#rid29">29</a>].</p><p>Most studies show that the mean time to nephrectomy is well over a year after withdrawal of immunosuppression in patients returning to dialysis therapy.</p><p class="headingAnchor" id="H2941402043"><span class="h3">Secondary adrenal insufficiency</span><span class="headingEndMark"> — </span>Although some patients have completed glucocorticoid withdrawal at the time of allograft failure, most patients returning to dialysis continue to receive long-term glucocorticoid therapy. These patients may be at risk for adrenal insufficiency following glucocorticoid withdrawal, although the evidence supporting this is controversial.</p><p>Dialysis patients with secondary adrenal insufficiency frequently present with subtle findings of isolated glucocorticoid insufficiency [<a href="#rid30">30,31</a>]. These include persistent fever, weakness, fatigability, myalgias, arthralgias, weight loss with subsequent fluid overload because of the lack of adequate ultrafiltration, mild hypercalcemia, and eosinophilia. In cases such as this, we typically administer low-dose <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> (0.05 to 0.1 mg/kg per day) to see if symptoms improve. If symptoms improve, we attempt a slower prednisone taper. (See  <a class="medical medical_review" href="/z/d/html/159.html" rel="external">"Clinical manifestations of adrenal insufficiency in adults"</a>.)</p><p>Some patients undergo glucocorticoid withdrawal without adverse effects despite an abnormal adrenocorticotropic hormone (ACTH) stimulation test (eg, cosyntropin stimulation test) or other laboratory evidence of adrenal insufficiency (see  <a class="medical medical_review" href="/z/d/html/154.html" rel="external">"Determining the etiology of adrenal insufficiency in adults"</a>). One study, for example, evaluated 21 kidney transplant recipients returning to dialysis; 14 initially displayed evidence of adrenal suppression as measured by either an ACTH challenge or an inadequate increase in plasma cortisol with insulin administration [<a href="#rid32">32</a>]. Although the withdrawal of glucocorticoids in all patients was associated with few adverse clinical events, 30 percent still had laboratory evidence of adrenal suppression when reassessed at six months.</p><p>In another series of 13 patients with kidney transplant failure who returned to dialysis, seven with a normal <a class="drug drug_general" data-topicid="9298" href="/z/d/drug information/9298.html" rel="external">ACTH stimulation test</a> were immediately removed from glucocorticoid therapy, while six with equivocal test results were tapered over one to two months [<a href="#rid33">33</a>]. These withdrawals occurred without an adverse effect.</p><p>Thus, although the <a class="drug drug_general" data-topicid="9298" href="/z/d/drug information/9298.html" rel="external">ACTH stimulation test</a> is the "gold standard" for diagnosing secondary adrenal insufficiency, a test that predicts the clinical response of patients in the setting of dialysis and concurrent withdrawal of long-term glucocorticoids remains to be established. In general, the length of time required to recover normal hypothalamic-pituitary-adrenal function depends upon the degree of suppression; this, in turn, depends upon the dose and duration of the glucocorticoid immunosuppressive therapy. The time varies from a few weeks to as long as nine months or more. (See  <a class="medical medical_review" href="/z/d/html/7983.html" rel="external">"Glucocorticoid withdrawal"</a>.)</p><p>Since the findings of adrenal insufficiency in this patient population may be subtle, conservative clinical judgment combined with careful laboratory evaluation should be employed. As an example, patients who tolerate glucocorticoid withdrawal under relatively nonstressful conditions may require a temporary increase in glucocorticoid dose during periods of stress. (See  <a class="medical medical_review" href="/z/d/html/7983.html" rel="external">"Glucocorticoid withdrawal"</a> and  <a class="medical medical_review" href="/z/d/html/155.html" rel="external">"Treatment of adrenal insufficiency in adults"</a>.)</p><p>The experience with glucocorticoid withdrawal in well-functioning kidney transplants demonstrates that gradual glucocorticoid withdrawal is not associated with symptomatic adrenal insufficiency. In a randomized trial of withdrawal of glucocorticoids over a four-month period, one year after kidney transplantation, only 1 of the 49 patients assigned to the withdrawal arm developed symptoms requiring reinstitution of low-dose <a class="drug drug_general" data-topicid="9808" href="/z/d/drug information/9808.html" rel="external">prednisolone</a> [<a href="#rid34">34</a>]. Thus, "stress-dose steroids" are rarely needed. (See  <a class="medical medical_review" href="/z/d/html/7356.html" rel="external">"Kidney transplantation in adults: Maintenance immunosuppressive therapy"</a>.)</p><p class="headingAnchor" id="H1698654887"><span class="h3">Loss of residual kidney function</span><span class="headingEndMark"> — </span>We have found that kidney allograft function deteriorates rapidly after withdrawal of immunosuppression in both hemodialysis and peritoneal dialysis patients. Thus, a longer taper of immunosuppression over a year may permit the maintenance of some kidney allograft function while on dialysis similar to nontransplant patients initiating dialysis therapy. Although residual kidney function is critical for the delivery of adequate doses of dialysis in patients undergoing peritoneal dialysis and is also a marker for mortality in hemodialysis patients [<a href="#rid35">35</a>], no studies have adequately addressed its importance in failed kidney allografts.</p><p class="headingAnchor" id="H2986805637"><span class="h3">Sensitization</span><span class="headingEndMark"> — </span>Kidney transplant recipients with a failing kidney allograft have an increased risk of developing de novo HLA sensitization [<a href="#rid36">36-39</a>]. This occurs most commonly in the setting of restarting dialysis and relisting for transplant, when immunosuppression is frequently modified or withdrawn:</p><p class="bulletIndent1"><span class="glyph">●</span>In a retrospective study of 119 patients with kidney allograft failure who had available panel reactive antibody (PRA) testing, the percentage of those who were highly sensitized increased from 21 percent at the time of graft failure to 68 percent after withdrawal of immunosuppression [<a href="#rid36">36</a>]; by contrast, only 8 percent of patients who maintained immunosuppression became highly sensitized.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Similar findings were reported in another study of 104 patients with a failed kidney transplant [<a href="#rid37">37</a>]. Among the 69 patients who did not have detectable anti-HLA antibodies at the time of graft loss, de novo anti-HLA antibodies were subsequently detected in 38 of 58 (66 percent) patients who had withdrawal of immunosuppression, compared with 0 of 11 of those who continued immunosuppression.</p><p></p><p>An overview of HLA sensitization in kidney transplantation is presented elsewhere. (See  <a class="medical medical_review" href="/z/d/html/116878.html" rel="external">"Kidney transplantation in adults: Overview of HLA sensitization and crossmatch testing"</a>.)</p><p class="headingAnchor" id="H2186629171"><span class="h1">TRANSPLANT NEPHRECTOMY</span><span class="headingEndMark"> — </span>Surgical removal of a kidney allograft (transplant nephrectomy) is commonly performed in patients who return to dialysis following failure of a kidney transplant [<a href="#rid40">40</a>]. Reported rates of transplant nephrectomy after graft failure range from 9 to 74 percent [<a href="#rid41">41-43</a>] and vary from center to center.</p><p>Most studies show that the mean time to nephrectomy is well over a year after withdrawal of immunosuppression in patients returning to dialysis therapy.</p><p class="headingAnchor" id="H1148788980"><span class="h2">Indications for nephrectomy</span><span class="headingEndMark"> — </span>The most common indications for transplant nephrectomy are the onset of symptoms and/or complications related to rejection after withdrawal of immunosuppression and a history of early graft failure (with or without symptoms and/or complications):</p><p class="bulletIndent1"><span class="glyph">●</span>Symptoms resulting from rejection and necrosis include graft tenderness, fever, hematuria, localized edema, and occasionally infection. Less fulminant rejection may present with unusual symptoms, such as weight loss, anemia, fatigue, gastrointestinal complaints, neurologic disturbances, and resistance to erythropoiesis-stimulating agents (ESAs). (See <a class="local">'Rejection'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients who have early graft failure (defined as a return to dialysis within one year of transplantation) are much more likely to develop a graft-related complication requiring nephrectomy than those with late allograft failure, independent of whether immunosuppressive medications are withdrawn. Although such complications may be observed in patients in whom withdrawal is not initiated, the abrupt withdrawal of immunosuppression among those with early graft failure increases the risk of precipitating rejection that requires nephrectomy. In addition, the morbidity and mortality from nephrectomy has improved markedly over the last three decades. These observations have led most centers to adopt a policy of immediate withdrawal of immunosuppression combined with preemptive nephrectomy for patients with early allograft failure [<a href="#rid44">44-46</a>]. (See <a class="local">'Early graft failure (&lt;1 year posttransplant)'</a> above.)</p><p></p><p>By comparison, the immediate withdrawal of immunosuppressive agents followed by nephrectomy is less commonly performed for patients with late graft failure (greater than one year) [<a href="#rid41">41</a>]. The possible indications for transplant nephrectomy in late allograft failure after initiation of dialysis are not clearly defined [<a href="#rid47">47</a>] but may be considered in patients with signs and symptoms of a chronic inflammatory state [<a href="#rid48">48,49</a>]. Some clinicians, for example, advocate allograft removal with features of such an inflammatory state [<a href="#rid49">49</a>], while others suggest nephrectomy only with symptoms [<a href="#rid50">50</a>]. (See  <a class="medical medical_review" href="/z/d/html/1939.html" rel="external">"Inflammation in patients with kidney function impairment"</a>.)</p><p class="headingAnchor" id="H311694936"><span class="h2">Outcomes after nephrectomy</span></p><p class="headingAnchor" id="H3989335607"><span class="h3">Patient survival</span><span class="headingEndMark"> — </span>Some, but not all, studies have suggested that transplant nephrectomy may improve patient survival. As an example, an analysis based upon the United States Renal Data System found that survival was improved after transplant nephrectomy [<a href="#rid51">51</a>]. Among nearly 11,000 dialysis patients with a failed kidney allograft, 32 percent underwent nephrectomy between 1994 and 2004. The relative risk for all-cause death was significantly lower for those with a transplant nephrectomy (adjusted hazard ratio [HR] 0.68, 95% CI 0.63-0.74). However, it is difficult to generalize these results, since the study has several flaws; these include unclear reasons for nephrectomy as well as not defining the comorbid conditions that prevented a nephrectomy. Thus, patients who underwent nephrectomy may have been healthier than those in whom a nephrectomy was not performed.</p><p>Another retrospective study found that transplant nephrectomy was associated with an increased risk of death (HR 1.13, 95% CI 1.01-1.26) when performed in patients with early graft loss (within the first posttransplant year) [<a href="#rid41">41</a>]. By contrast, a decreased risk of death (HR 0.89, 95% CI 0.83-0.95) was observed among patients with late graft loss (after the first posttransplant year). Whether survival is truly improved with nephrectomy requires additional evidence.</p><p class="headingAnchor" id="H2112167129"><span class="h3">Surgical morbidity and mortality</span><span class="headingEndMark"> — </span>Transplant nephrectomy is associated with the following postoperative morbidity and mortality:</p><p class="bulletIndent1"><span class="glyph">●</span>Postoperative mortality following transplant nephrectomy ranges from 0 to 11 percent [<a href="#rid42">42,52-58</a>]; the most common cause of death is infection. Other causes of death include intravascular coagulation, intestinal ischemia, and bleeding.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The most common complications after transplant nephrectomy include postoperative bleeding and hematoma [<a href="#rid42">42,43,52-54,56-58</a>]. Other complications include infection, lymphocele, abscess formation, and deep vein thrombosis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In two studies, complication rates were higher among patients undergoing transplant nephrectomy for early graft failure compared with those undergoing nephrectomy for late graft failure (59 versus 22 percent and 59 versus 12 percent, respectively) [<a href="#rid55">55,56</a>]. One possible explanation for this difference is that transplant nephrectomies performed for early graft failure are frequently performed for urgent indications (such as hemorrhage or thrombosis).</p><p></p><p class="headingAnchor" id="H2575538468"><span class="h3">Effects on sensitization</span><span class="headingEndMark"> — </span>Several small studies have showed that transplant nephrectomy is associated with human leukocyte antigen (HLA) antibody sensitization:</p><p class="bulletIndent1"><span class="glyph">●</span>In two series, panel reactive antibody (PRA) levels of greater than 30 percent were more frequent in patients who had undergone transplant nephrectomy (57 versus 33 percent and 60 versus 30 percent, respectively) [<a href="#rid59">59,60</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Another report examined 52 patients awaiting kidney transplantation, of whom 12 and 14 underwent elective transplant nephrectomy and nephrectomy for symptoms, respectively [<a href="#rid28">28</a>]. Patients with nephrectomy were more likely to have a PRA of greater than 50 percent than those without nephrectomy (54 versus 15 percent); patients undergoing symptomatic nephrectomy had the highest peak titer PRA.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A review of 78 patients with allograft failure after six months and rapid immunosuppression tapering reported an increase in PRA after nephrectomy [<a href="#rid61">61</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a study using a highly sensitive, microbead-based, single-antigen assay, the incidence of donor-specific antibody (DSA) reactivity to HLA-A, HLA-B, and HLA-DRB1 antigen mismatches was significantly lower before than after allograft removal (64 percent versus 87 percent, respectively, for HLA-A and -B, and 57 percent versus 86 percent, respectively, for HLA-DRB1). However, the difference in the incidence of DSA reactivity to HLA-DR51⁄DR52⁄DR53 and HLA-DQ antigen mismatches was small and statistically insignificant [<a href="#rid62">62</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In another study that used the microbead assay, at a mean last follow-up of 538±347 days, the incidence of DSA reactivity was higher among 48 patients who had undergone nephrectomy, compared with 21 patients who had not undergone nephrectomy after allograft loss (52 versus 81 percent, respectively) [<a href="#rid63">63</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a single-center, retrospective study that include 119 patients with available PRA testing, the risk of having class I or class II PRA of &gt;80 percent was correlated with the HLA mismatch of the kidney, African-American race, and complete withdrawal of immunosuppression within 120 days of graft failure [<a href="#rid36">36</a>]. Nephrectomy had no impact on PRA in the multivariate analysis in this study. Eighty percent of the study population had withdrawn immunosuppression, and 33 percent required transplant nephrectomy. No patient who remained on immunosuppression required nephrectomy, although a subsequent analysis of a larger group of patients from the same investigators demonstrated a 23 percent incidence of nephrectomy in the group continued on immunosuppression [<a href="#rid13">13,36</a>].</p><p></p><p>These studies suggest that it is not advisable to routinely perform a transplant nephrectomy after graft failure. Immediate withdrawal of immunosuppression is associated with an increased need for transplant nephrectomy, which is associated with HLA sensitization. It is not clear whether long-term continuation of immunosuppression prevents sensitization in patients who are being considered for retransplantation.</p><p class="headingAnchor" id="H3336785720"><span class="h3">Effects on retransplantation</span><span class="headingEndMark"> — </span>An unresolved issue is whether there might be some benefit for retransplantation from leaving the failed graft in place. Animal models of retransplantation have demonstrated that, to maintain tolerance and accept a second graft, the presence of donor antigen is beneficial. As an example, T cells adoptively transferred to an irradiated host may revert to a normal state of responsiveness in an antigen-free animal as opposed to an animal that bears the donor antigen [<a href="#rid64">64</a>]. In addition, in a rat heart transplantation model, graftectomy resulted in significantly reduced survival of the second allograft, thereby suggesting a tolerizing effect of residual antigen [<a href="#rid65">65</a>]. Although this hypothesis has not been tested in humans, antigen-specific hyporeactivity induced by pretransplantation blood transfusions suggests that this mechanism is plausible [<a href="#rid66">66</a>].</p><p>In humans, however, there appears to be no clinically significant difference in outcome after retransplantation among those with or without nephrectomy in the small, retrospective studies that have addressed this question. In addition, despite the above retrospective findings linking nephrectomy and sensitization, there is no proven causal relationship between nephrectomy and subsequent high PRA levels. (See <a class="local">'Effects on sensitization'</a> above.)</p><p class="headingAnchor" id="H3344878603"><span class="h2">Nonsurgical alternatives</span><span class="headingEndMark"> — </span>Although nephrectomy is the conventional approach to removing failed kidney allografts, some centers have reported some success with vascular embolization [<a href="#rid67">67,68</a>]. Further study is required to delineate the role for this technique in this setting, with some concern related to mortality and the absence of data with hematologic and biochemical outcomes [<a href="#rid49">49</a>].</p><p class="headingAnchor" id="H4143523757"><span class="h1">DIALYSIS AFTER GRAFT FAILURE</span><span class="headingEndMark"> — </span>Patients may require dialysis after their transplanted kidney has failed. This may occur many years after the transplantation. The indications for initiating maintenance dialysis among transplant recipients with a failing allograft are the same as for nontransplant patients with end-stage kidney disease (ESKD). (See  <a class="medical medical_review" href="/z/d/html/1866.html" rel="external">"Indications for initiation of dialysis in chronic kidney disease", section on 'Indications for initiation of chronic dialysis'</a>.)</p><p class="headingAnchor" id="H383301045"><span class="h2">Timing of dialysis initiation</span><span class="headingEndMark"> — </span>Given the high mortality, the appropriate timing of dialysis initiation and the aggressive management of comorbid conditions associated with chronic kidney disease (CKD) are critical in optimizing survival in patients with a failing allograft. Unfortunately, it is common to delay the initiation of dialysis after graft loss until clearances have fallen well below recommended targets [<a href="#rid69">69</a>]. Earlier attention to markers for graft failure, such as proteinuria, decrease in kidney function of &gt;30 percent, recurrent disease, or transplant glomerulopathy, to initiate CKD planning may improve outcomes.</p><p>In addition, patients commonly initiate dialysis with a central venous catheter rather than the preferred arteriovenous fistula despite the well-recognized infection risk associated with catheters. (See  <a class="medical medical_review" href="/z/d/html/1843.html" rel="external">"Central venous catheters for acute and chronic hemodialysis access and their management"</a>.)</p><p>This was demonstrated in the following retrospective studies:</p><p class="bulletIndent1"><span class="glyph">●</span>In an analysis of 16,728 patients with failed transplants who initiated dialysis between January 2006 and September 2011, 65 percent initiated dialysis with a central venous catheter [<a href="#rid70">70</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Among 683 patients who started dialysis after allograft failure, 47 percent had a vascular access created in the 24 months after initiation of dialysis, and only 16 percent had an access created in the 12 months prior to dialysis initiation [<a href="#rid71">71</a>]. Coronary artery disease, diabetes, and peritoneal dialysis prior to transplantation were associated with lower rates of predialysis access creation.</p><p></p><p>The detriment of this approach is suggested in an analysis of 186 patients returning to dialysis where 40 percent of infections were dialysis catheter-related bacteremia episodes, with the six-month absolute risk in patients on immunosuppression being 12 versus 8 percent in patients weaned from immunosuppression [<a href="#rid13">13</a>]. This may be particularly concerning in patients with diabetes who have a significantly increased risk of infection-related death after transplant failure compared with patients with glomerulonephritis or hypertension [<a href="#rid5">5</a>].</p><p class="headingAnchor" id="H3431133448"><span class="h2">Dialysis modality</span><span class="headingEndMark"> — </span>The optimal dialysis modality after allograft loss is unclear. In general, the choice between hemodialysis and peritoneal dialysis generally depends upon factors that are unrelated to transplantation. Similar survival rates have been reported with peritoneal dialysis and hemodialysis [<a href="#rid72">72-74</a>].</p><p>One study suggested that patient survival and peritonitis-free survival are similar in those with failed allograft function who subsequently undergo peritoneal dialysis compared with those who undergo peritoneal dialysis after the loss of native kidney function [<a href="#rid75">75</a>]. This differs from studies of patients on hemodialysis that have shown increased mortality among patients who have had a transplant. However, follow-up was limited to 15 months in this study, and we do not believe that these are sufficient data to recommend peritoneal dialysis.</p><p>Given the high mortality associated with the return to dialysis after transplantation, it may be reasonable to consider a more intensive dialysis regimen (such as daily hemodialysis) than conventional hemodialysis or peritoneal dialysis in patients after allograft loss. However, a patient survival benefit of these therapies has not been demonstrated among transplant patients. (See  <a class="medical medical_review" href="/z/d/html/1898.html" rel="external">"Short daily hemodialysis"</a> and  <a class="medical medical_review" href="/z/d/html/1959.html" rel="external">"Outcomes associated with nocturnal hemodialysis"</a>.)</p><p class="headingAnchor" id="H2391916474"><span class="h2">Prognosis</span><span class="headingEndMark"> — </span>Patients who return to dialysis after graft loss have a high mortality rate, even when compared with dialysis patients who have never received a transplant [<a href="#rid5">5,76</a>]. As an example, a study of Scientific Registry of Transplant Recipients (SRTR) data demonstrated a 78 percent increase in mortality among patients who returned to dialysis after a transplant compared with those on the transplant waiting list [<a href="#rid76">76</a>]. When results were analyzed at different intervals after graft failure, the largest increase in mortality was noted during the first week after graft failure.</p><p>Mortality is considerably higher than in patients who have continued allograft function [<a href="#rid5">5,76,77</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>In general, less than 40 percent of such patients survive 10 years as compared with more than 75 percent of patients with a functioning kidney transplant [<a href="#rid5">5</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The annual adjusted death rate is over three times higher than the death rate during the period of time when the transplant is functioning (9.42 versus 2.81 per 100 patient-years) [<a href="#rid5">5</a>].</p><p></p><p>The exact reasons for the increased mortality are undefined but are likely to be related in part to the recurrence of kidney failure independent of a requirement for dialysis. In one study, the increase in serum creatinine one year after transplantation was directly related to cardiovascular mortality [<a href="#rid77">77</a>]. Transplant recipients who return to dialysis also tend to lose residual kidney function quickly; loss of residual kidney function is associated with increased mortality [<a href="#rid72">72,78,79</a>]. (See  <a class="medical medical_review" href="/z/d/html/1847.html" rel="external">"Patient survival and maintenance dialysis", section on 'Residual kidney function'</a> and  <a class="medical medical_review" href="/z/d/html/1941.html" rel="external">"Residual kidney function in kidney failure", section on 'Clinical importance of residual kidney function'</a>.)</p><p class="headingAnchor" id="H1240220392"><span class="h1">RETRANSPLANTATION</span><span class="headingEndMark"> — </span>We suggest preemptive transplantation for most patients after the first transplanted kidney has failed. This is consistent with the 2014 British Transplantation Society Guidelines for the Management of the Failing Kidney Transplant [<a href="#rid19">19</a>]. The one exception is when the first transplanted kidney has failed within one year. In such patients, we suggest a short period of dialysis (one to four weeks) prior to transplantation, rather than preemptive transplantation.</p><p>In addition, we agree with the British Transplantation Society Guidelines that suitable patients should be evaluated for repeat transplantation when graft survival is estimated to be less than one year [<a href="#rid19">19</a>].</p><p>Prolonged waiting times for a second kidney transplant are associated with inferior graft and patient outcomes [<a href="#rid80">80</a>]. In one study of 911 recipients of a second kidney transplant, the relative risk of acute rejection at six months, overall graft failure, and all-cause mortality increased by 11, 6, and 13 percent, respectively, for every one-year increase in waiting time before the second transplant.</p><p>Preemptive transplantation is preferred for most patients because overall graft and patient survival has been shown to be substantially better among patients who receive a preemptive second transplant compared with patients who receive a second transplant after a period of dialysis [<a href="#rid81">81</a>]. In one study, preemptive second transplantation, compared with nonpreemptive second transplantation, was associated with a decreased risk of graft failure due to any cause (hazard ratio [HR] 0.88, 95% CI 0.81-0.96) and death with a functioning allograft (HR 0.76, 95% CI 0.66-0.87). The risk of death-censored graft failure was the same between groups.</p><p>Patients who have early failure of the first kidney transplant (ie, less than one year from transplantation) may have improved graft survival with a short period of dialysis prior to a second transplantation. Analyses of United States Renal Data System data have shown a 34 to 36 percent higher risk of graft failure in patients who undergo preemptive retransplantation in comparison with those retransplanted after a period of dialysis (more than six days) [<a href="#rid81">81,82</a>].</p><p>Among patients with early graft failure of the first transplanted kidney, the optimal duration of dialysis prior to the second transplant is not known. In the studies cited above, increased waiting time after graft loss increased mortality [<a href="#rid80">80,82</a>]. Thus, we avoid a prolonged period of dialysis prior to the second transplant.</p><p class="headingAnchor" id="H1625965755"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/110754.html" rel="external">"Society guideline links: Kidney transplantation"</a>.)</p><p class="headingAnchor" id="H13"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>General principles</strong> – Over the last few decades, the long-term survival of kidney allografts has significantly increased. Despite this success, a substantial number of kidney transplant recipients eventually require the permanent reinstitution of kidney replacement therapy because of allograft failure. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management of immunosuppression</strong> – One of the most important aspects of managing the patient with a failing kidney allograft is deciding when and how to safely stop maintenance immunosuppressive therapy. In general, the primary goal is to withdraw the immunosuppressive agents without precipitating rejection, causing any adverse effects related to drug withdrawal, or exacerbating allosensitization. Secondarily, the impact of sensitization should be considered for those patients pursuing another transplant. Continuation of immunosuppression might be necessary in patients who are felt to be too frail to tolerate a transplant nephrectomy, which is a major operation. Our approach is as follows (<a class="graphic graphic_algorithm graphicRef121542" href="/z/d/graphic/121542.html" rel="external">algorithm 1</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In patients with kidney allograft failure that occurs &lt;1 year posttransplant (early allograft failure), we suggest preemptive nephrectomy and immediate withdrawal of immunosuppression at the time of nephrectomy (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Early graft failure (&lt;1 year posttransplant)'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In patients with kidney allograft failure that occurs &gt;1 year posttransplant (late allograft failure), we suggest a gradual withdrawal of immunosuppression, rather than preemptive nephrectomy and immediate withdrawal of immunosuppression (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Our specific approach differs depending upon whether or not the patient is likely to receive another kidney transplant within one year and upon the patient's residual kidney function. All patients should be closely monitored for symptoms of rejection and secondary adrenal insufficiency. (See <a class="local">'Late graft failure (&gt;1 year posttransplant)'</a> above and <a class="local">'Monitoring during withdrawal of immunosuppression'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Complications of withdrawing immunosuppression</strong> – Withdrawal of immunosuppression may be associated with significant complications, including precipitation of rejection possibly requiring allograft nephrectomy, secondary adrenal insufficiency, loss of residual kidney function, potentially adverse immunologic effects among those pursuing another transplantation, and worsening anemia due to erythropoiesis-stimulating agent (ESA) resistance. (See <a class="local">'Complications of withdrawal'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications for transplant nephrectomy</strong> – Surgical removal of a kidney allograft (transplant nephrectomy) is commonly performed in patients who return to dialysis following failure of a kidney transplant. The most common indications for transplant nephrectomy are the onset of symptoms and/or complications related to rejection after withdrawal of immunosuppression and a history of early graft failure (with or without symptoms and/or complications). (See <a class="local">'Indications for nephrectomy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dialysis after graft failure</strong> – Patients may require dialysis after their transplanted kidney has failed. This may occur many years after the transplantation. Patients who return to chronic dialysis after a transplanted kidney has failed have a high mortality rate compared with patients with a functioning allograft and also when compared with dialysis patients who have not received a kidney transplant. The indications for initiating maintenance dialysis among transplant recipients with a failing allograft are the same as for nontransplant patients with end-stage kidney disease (ESKD). (See <a class="local">'Dialysis after graft failure'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Retransplantation</strong> – For most patients with kidney allograft failure occurring &lt;1 year posttransplant, we suggest a short period of dialysis (one to four weeks) prior to transplantation, rather than preemptive transplantation (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). For most patients with kidney allograft failure occurring &gt;1 year posttransplantation, we suggest preemptive transplantation, rather than a period of dialysis prior to transplantation (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Retransplantation'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Poggio ED, Augustine JJ, Arrigain S, et al. Long-term kidney transplant graft survival-Making progress when most needed. Am J Transplant 2021; 21:2824.</a></li><li class="breakAll">https://optn.transplant.hrsa.gov/data/view-data-reports/national-data/ (Accessed on March 06, 2019).</li><li class="breakAll">UNOS Registry Data www.optn.org (Accessed on February 01, 2009).</li><li class="breakAll">Organ Procurement and Transplantation Network, 2019, data request.</li><li><a class="nounderline abstract_t">Kaplan B, Meier-Kriesche HU. Death after graft loss: an important late study endpoint in kidney transplantation. Am J Transplant 2002; 2:970.</a></li><li><a class="nounderline abstract_t">Gill JS, Abichandani R, Khan S, et al. Opportunities to improve the care of patients with kidney transplant failure. Kidney Int 2002; 61:2193.</a></li><li><a class="nounderline abstract_t">Knoll G, Muirhead N, Trpeski L, et al. Patient survival following renal transplant failure in Canada. Am J Transplant 2005; 5:1719.</a></li><li><a class="nounderline abstract_t">Kendrick EA, Davis CL. Managing the failing allograft. Semin Dial 2005; 18:529.</a></li><li><a class="nounderline abstract_t">Gill JS, Abichandani R, Kausz AT, Pereira BJ. Mortality after kidney transplant failure: the impact of non-immunologic factors. Kidney Int 2002; 62:1875.</a></li><li><a class="nounderline abstract_t">Gregoor PJ, Kramer P, Weimar W, van Saase JL. Infections after renal allograft failure in patients with or without low-dose maintenance immunosuppression. Transplantation 1997; 63:1528.</a></li><li><a class="nounderline abstract_t">Smak Gregoor PJ, Zietse R, van Saase JL, et al. Immunosuppression should be stopped in patients with renal allograft failure. Clin Transplant 2001; 15:397.</a></li><li><a class="nounderline abstract_t">Kiberd BA, Belitsky P. The fate of the failed renal transplant. Transplantation 1995; 59:645.</a></li><li><a class="nounderline abstract_t">Woodside KJ, Schirm ZW, Noon KA, et al. Fever, infection, and rejection after kidney transplant failure. Transplantation 2014; 97:648.</a></li><li><a class="nounderline abstract_t">Pham PT, Pham PC. Immunosuppressive management of dialysis patients with recently failed transplants. Semin Dial 2011; 24:307.</a></li><li><a class="nounderline abstract_t">van Leeuwen MT, Webster AC, McCredie MR, et al. Effect of reduced immunosuppression after kidney transplant failure on risk of cancer: population based retrospective cohort study. BMJ 2010; 340:c570.</a></li><li><a class="nounderline abstract_t">Vajdic CM, van Leeuwen MT, Webster AC, et al. Cutaneous melanoma is related to immune suppression in kidney transplant recipients. Cancer Epidemiol Biomarkers Prev 2009; 18:2297.</a></li><li><a class="nounderline abstract_t">Burn DJ, Bates D. Neurology and the kidney. J Neurol Neurosurg Psychiatry 1998; 65:810.</a></li><li><a class="nounderline abstract_t">Bennett WM. The failed renal transplant: in or out? Semin Dial 2005; 18:188.</a></li><li><a class="nounderline abstract_t">Andrews PA, Standards Committee of the British Transplantation Society. Summary of the British Transplantation Society Guidelines for Management of the Failing Kidney Transplant. Transplantation 2014; 98:1130.</a></li><li><a class="nounderline abstract_t">Lubetzky M, Tantisattamo E, Molnar MZ, et al. The failing kidney allograft: A review and recommendations for the care and management of a complex group of patients. Am J Transplant 2021; 21:2937.</a></li><li><a class="nounderline abstract_t">Alhamad T, Lubetzky M, Lentine KL, et al. Kidney recipients with allograft failure, transition of kidney care (KRAFT): A survey of contemporary practices of transplant providers. Am J Transplant 2021; 21:3034.</a></li><li><a class="nounderline abstract_t">Solid CA, Foley RN, Gill JS, et al. Epoetin use and Kidney Disease Outcomes Quality Initiative hemoglobin targets in patients returning to dialysis with failed renal transplants. Kidney Int 2007; 71:425.</a></li><li><a class="nounderline abstract_t">Madore F, Hébert MJ, Leblanc M, et al. Determinants of late allograft nephrectomy. Clin Nephrol 1995; 44:284.</a></li><li><a class="nounderline abstract_t">Thomas PP, Jacob CK, Kirubakaran MG, et al. Indication for routine allograft nephrectomy in cases of irreversible rejection. Transplantation 1989; 48:155.</a></li><li><a class="nounderline abstract_t">DiSesa VJ, Tilney NL. Conservative management of the failed renal allograft: indications for transplant nephrectomy. Curr Surg 1982; 39:417.</a></li><li><a class="nounderline abstract_t">Freier DT, Haines RF, Rosenzweig J, et al. Sequential renal transplants: some surgical and immunological implications on management of the first homograft. Surgery 1976; 79:262.</a></li><li><a class="nounderline abstract_t">Noel C, Hazzan M, Boukelmoune M, et al. Indication for allograft nephrectomy after irreversible rejection: is there an ideal delay? Transplant Proc 1997; 29:145.</a></li><li><a class="nounderline abstract_t">Gourlay WA, Patterson R, Gill J, et al. Influence of transplant nephrectomy on panel reactive antibody titer and waiting time for second kidney transplants (abstract). Transplantation 1999; 67:S169.</a></li><li><a class="nounderline abstract_t">Matzinger P. Graft tolerance: a duel of two signals. Nat Med 1999; 5:616.</a></li><li><a class="nounderline abstract_t">Verresen L, Vanrenterghem Y, Waer M, et al. Corticosteroid withdrawal syndrome in dialysis patients. Nephrol Dial Transplant 1988; 3:476.</a></li><li><a class="nounderline abstract_t">Sever MS, Türkmen A, Yildiz A, et al. Fever in dialysis patients with recently rejected renal allografts. Int J Artif Organs 1998; 21:403.</a></li><li><a class="nounderline abstract_t">Rodger RS, Watson MJ, Sellars L, et al. Hypothalamic-pituitary-adrenocortical suppression and recovery in renal transplant patients returning to maintenance dialysis. Q J Med 1986; 61:1039.</a></li><li><a class="nounderline abstract_t">Shapiro R, Carroll PB, Tzakis AG, et al. Adrenal reserve in renal transplant recipients with cyclosporine, azathioprine, and prednisone immunosuppression. Transplantation 1990; 49:1011.</a></li><li><a class="nounderline abstract_t">Ratcliffe PJ, Dudley CR, Higgins RM, et al. Randomised controlled trial of steroid withdrawal in renal transplant recipients receiving triple immunosuppression. Lancet 1996; 348:643.</a></li><li><a class="nounderline abstract_t">Lameire NH. The impact of residual renal function on the adequacy of peritoneal dialysis. Nephron 1997; 77:13.</a></li><li><a class="nounderline abstract_t">Augustine JJ, Woodside KJ, Padiyar A, et al. Independent of nephrectomy, weaning immunosuppression leads to late sensitization after kidney transplant failure. Transplantation 2012; 94:738.</a></li><li><a class="nounderline abstract_t">Scornik JC, Kriesche HU. Human leukocyte antigen sensitization after transplant loss: timing of antibody detection and implications for prevention. Hum Immunol 2011; 72:398.</a></li><li><a class="nounderline abstract_t">Casey MJ, Wen X, Kayler LK, et al. Prolonged immunosuppression preserves nonsensitization status after kidney transplant failure. Transplantation 2014; 98:306.</a></li><li><a class="nounderline abstract_t">Singh P, Filippone EJ, Colombe BW, et al. Sensitization trends after renal allograft failure: the role of DQ eplet mismatches in becoming highly sensitized. Clin Transplant 2016; 30:71.</a></li><li><a class="nounderline abstract_t">Ghyselen L, Naesens M. Indications, risks and impact of failed allograft nephrectomy. Transplant Rev (Orlando) 2019; 33:48.</a></li><li><a class="nounderline abstract_t">Johnston O, Rose C, Landsberg D, et al. Nephrectomy after transplant failure: current practice and outcomes. Am J Transplant 2007; 7:1961.</a></li><li><a class="nounderline abstract_t">Mazzucchi E, Nahas WC, Antonopoulos IM, et al. Surgical complications of graft nephrectomy in the modern transplant era. J Urol 2003; 170:734.</a></li><li><a class="nounderline abstract_t">Secin FP, Rovegno AR, del Rosario Brunet M, et al. Cumulative incidence, indications, morbidity and mortality of transplant nephrectomy and the most appropriate time for graft removal: only nonfunctioning transplants that cause intractable complications should be excised. J Urol 2003; 169:1242.</a></li><li><a class="nounderline abstract_t">Vanrenterghem Y, Khamis S. The management of the failed renal allograft. Nephrol Dial Transplant 1996; 11:955.</a></li><li><a class="nounderline abstract_t">Roberts CS, LaFond J, Fitts CT, et al. New patterns of transplant nephrectomy in the cyclosporine era. J Am Coll Surg 1994; 178:59.</a></li><li><a class="nounderline abstract_t">O'Sullivan DC, Murphy DM, McLean P, Donovan MG. Transplant nephrectomy over 20 years: factors involved in associated morbidity and mortality. J Urol 1994; 151:855.</a></li><li><a class="nounderline abstract_t">Bia M. Indications for nephrectomy of a failed transplant. Semin Dial 1998; 11:196.</a></li><li><a class="nounderline abstract_t">López-Gómez JM, Pérez-Flores I, Jofré R, et al. Presence of a failed kidney transplant in patients who are on hemodialysis is associated with chronic inflammatory state and erythropoietin resistance. J Am Soc Nephrol 2004; 15:2494.</a></li><li><a class="nounderline abstract_t">Ayus JC, Achinger SG. At the peril of dialysis patients: ignoring the failed transplant. Semin Dial 2005; 18:180.</a></li><li><a class="nounderline abstract_t">Langone AJ, Chuang P. The management of the failed renal allograft: an enigma with potential consequences. Semin Dial 2005; 18:185.</a></li><li><a class="nounderline abstract_t">Ayus JC, Achinger SG, Lee S, et al. Transplant nephrectomy improves survival following a failed renal allograft. J Am Soc Nephrol 2010; 21:374.</a></li><li><a class="nounderline abstract_t">Vavallo A, Lucarelli G, Bettocchi C, et al. Allograft nephrectomy: what is the best surgical technique? Transplant Proc 2012; 44:1922.</a></li><li><a class="nounderline abstract_t">Toth F, Zadori G, Fedor R, et al. A Single-center Experience of Allograft Nephrectomies Following Kidney Transplantation. Transplant Proc 2016; 48:2552.</a></li><li><a class="nounderline abstract_t">Bonilla AJ, Alfaro AG, Henández JP, et al. Review of a transplantectomy series. Transplant Proc 2015; 47:81.</a></li><li><a class="nounderline abstract_t">Freitas R, Malheiro J, Santos C, et al. Allograft nephrectomy: a single-institution, 10-year experience. Transplant Proc 2015; 47:992.</a></li><li><a class="nounderline abstract_t">Sun IO, Hong YA, Park HS, et al. Comparison of the clinical characteristics of renal transplant recipients who underwent early versus late graft nephrectomy. Transplant Proc 2013; 45:2953.</a></li><li><a class="nounderline abstract_t">Touma NJ, Sener A, Caumartin Y, et al. Extracapsular versus intracapsular allograft nephrectomy: impact on allosensitization and surgical outcomes. Can Urol Assoc J 2011; 5:49.</a></li><li><a class="nounderline abstract_t">Emiroğlu R, Sevmiş S, Moray G, et al. One center's experience with allograft nephrectomy. Transplant Proc 2003; 35:2668.</a></li><li><a class="nounderline abstract_t">Sumrani N, Delaney V, Hong JH, et al. The influence of nephrectomy of the primary allograft on retransplant graft outcome in the cyclosporine era. Transplantation 1992; 53:52.</a></li><li><a class="nounderline abstract_t">Douzdjian V, Rice JC, Carson RW, et al. Renal retransplants: effect of primary allograft nephrectomy on early function, acute rejection and outcome. Clin Transplant 1996; 10:203.</a></li><li><a class="nounderline abstract_t">Khakhar AK, Shahinian VB, House AA, et al. The impact of allograft nephrectomy on percent panel reactive antibody and clinical outcome. Transplant Proc 2003; 35:862.</a></li><li><a class="nounderline abstract_t">Marrari M, Duquesnoy RJ. Detection of donor-specific HLA antibodies before and after removal of a rejected kidney transplant. Transpl Immunol 2010; 22:105.</a></li><li><a class="nounderline abstract_t">Del Bello A, Congy-Jolivet N, Sallusto F, et al. Donor-specific antibodies after ceasing immunosuppressive therapy, with or without an allograft nephrectomy. Clin J Am Soc Nephrol 2012; 7:1310.</a></li><li><a class="nounderline abstract_t">Ramsdell F, Fowlkes BJ. Maintenance of in vivo tolerance by persistence of antigen. Science 1992; 257:1130.</a></li><li><a class="nounderline abstract_t">Nishinaka H, Nakafusa Y, Hirano T, et al. Graft persistence effectively induces and maintains donor-specific unresponsiveness. J Surg Res 1997; 68:145.</a></li><li><a class="nounderline abstract_t">Jackson A, McSherry C, Butters K, et al. Pretransplant exposure to donor HLA-DR antigen in random transfusion units and the development of donor antigen-specific hyporeactivity. Hum Immunol 1997; 55:148.</a></li><li><a class="nounderline abstract_t">Delgado P, Diaz F, Gonzalez A, et al. Intolerance syndrome in failed renal allografts: incidence and efficacy of percutaneous embolization. Am J Kidney Dis 2005; 46:339.</a></li><li><a class="nounderline abstract_t">Cofan F, Real MI, Vilardell J, et al. Percutaneous renal artery embolisation of non-functioning renal allografts with clinical intolerance. Transpl Int 2002; 15:149.</a></li><li><a class="nounderline abstract_t">Arias M, Escallada R, de Francisco AL, et al. Return to dialysis after renal transplantation. Which would be the best way? Kidney Int Suppl 2002; :85.</a></li><li><a class="nounderline abstract_t">Chan MR, Oza-Gajera B, Chapla K, et al. Initial vascular access type in patients with a failed renal transplant. Clin J Am Soc Nephrol 2014; 9:1225.</a></li><li><a class="nounderline abstract_t">Zhang JC, Al-Jaishi A, Perl J, et al. Hemodialysis Arteriovenous Vascular Access Creation After Kidney Transplant Failure. Am J Kidney Dis 2015; 66:646.</a></li><li><a class="nounderline abstract_t">de Jonge H, Bammens B, Lemahieu W, et al. Comparison of peritoneal dialysis and haemodialysis after renal transplant failure. Nephrol Dial Transplant 2006; 21:1669.</a></li><li><a class="nounderline abstract_t">Perl J, Hasan O, Bargman JM, et al. Impact of dialysis modality on survival after kidney transplant failure. Clin J Am Soc Nephrol 2011; 6:582.</a></li><li><a class="nounderline abstract_t">Perl J, Dong J, Rose C, et al. Is dialysis modality a factor in the survival of patients initiating dialysis after kidney transplant failure? Perit Dial Int 2013; 33:618.</a></li><li><a class="nounderline abstract_t">Badve SV, Hawley CM, McDonald SP, et al. Effect of previously failed kidney transplantation on peritoneal dialysis outcomes in the Australian and New Zealand patient populations. Nephrol Dial Transplant 2006; 21:776.</a></li><li><a class="nounderline abstract_t">Rao PS, Schaubel DE, Jia X, et al. Survival on dialysis post-kidney transplant failure: results from the Scientific Registry of Transplant Recipients. Am J Kidney Dis 2007; 49:294.</a></li><li><a class="nounderline abstract_t">Meier-Kriesche HU, Baliga R, Kaplan B. Decreased renal function is a strong risk factor for cardiovascular death after renal transplantation. Transplantation 2003; 75:1291.</a></li><li><a class="nounderline abstract_t">Madar H, Korzets A, Ori Y, et al. Residual renal function in peritoneal dialysis after renal transplant failure. Perit Dial Int 2010; 30:470.</a></li><li><a class="nounderline abstract_t">Bernardo A, Fonseca I, Rodrigues A, et al. Predictors of residual renal function loss in peritoneal dialysis: is previous renal transplantation a risk factor? Adv Perit Dial 2009; 25:110.</a></li><li><a class="nounderline abstract_t">Wong G, Chua S, Chadban SJ, et al. Waiting Time Between Failure of First Graft and Second Kidney Transplant and Graft and Patient Survival. Transplantation 2016; 100:1767.</a></li><li><a class="nounderline abstract_t">Johnston O, Rose CL, Gill JS, Gill JS. Risks and benefits of preemptive second kidney transplantation. Transplantation 2013; 95:705.</a></li><li><a class="nounderline abstract_t">Goldfarb-Rumyantzev AS, Hurdle JF, Baird BC, et al. The role of pre-emptive re-transplant in graft and recipient outcome. Nephrol Dial Transplant 2006; 21:1355.</a></li></ol></div><div id="topicVersionRevision">Topic 7320 Version 22.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33346917" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Long-term kidney transplant graft survival-Making progress when most needed.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33346917" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Long-term kidney transplant graft survival-Making progress when most needed.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33346917" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Long-term kidney transplant graft survival-Making progress when most needed.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33346917" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Long-term kidney transplant graft survival-Making progress when most needed.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12482151" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Death after graft loss: an important late study endpoint in kidney transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12028460" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Opportunities to improve the care of patients with kidney transplant failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15943631" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Patient survival following renal transplant failure in Canada.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16398717" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Managing the failing allograft.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12371992" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Mortality after kidney transplant failure: the impact of non-immunologic factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9175823" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Infections after renal allograft failure in patients with or without low-dose maintenance immunosuppression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11737116" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Immunosuppression should be stopped in patients with renal allograft failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7878774" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : The fate of the failed renal transplant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24637864" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Fever, infection, and rejection after kidney transplant failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21564300" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Immunosuppressive management of dialysis patients with recently failed transplants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20150194" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Effect of reduced immunosuppression after kidney transplant failure on risk of cancer: population based retrospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19622722" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Cutaneous melanoma is related to immune suppression in kidney transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9854955" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Neurology and the kidney.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15934960" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : The failed renal transplant: in or out?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25299519" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Summary of the British Transplantation Society Guidelines for Management of the Failing Kidney Transplant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34115439" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : The failing kidney allograft: A review and recommendations for the care and management of a complex group of patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33559315" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Kidney recipients with allograft failure, transition of kidney care (KRAFT): A survey of contemporary practices of transplant providers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17213875" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Epoetin use and Kidney Disease Outcomes Quality Initiative hemoglobin targets in patients returning to dialysis with failed renal transplants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8605707" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Determinants of late allograft nephrectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2665222" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Indication for routine allograft nephrectomy in cases of irreversible rejection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6759066" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Conservative management of the failed renal allograft: indications for transplant nephrectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/769212" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Sequential renal transplants: some surgical and immunological implications on management of the first homograft.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9122935" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Indication for allograft nephrectomy after irreversible rejection: is there an ideal delay?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Influence of transplant nephrectomy on panel reactive antibody titer and waiting time for second kidney transplants (abstract)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10371494" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Graft tolerance: a duel of two signals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3140138" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Corticosteroid withdrawal syndrome in dialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9745995" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Fever in dialysis patients with recently rejected renal allografts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3310063" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Hypothalamic-pituitary-adrenocortical suppression and recovery in renal transplant patients returning to maintenance dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2336689" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Adrenal reserve in renal transplant recipients with cyclosporine, azathioprine, and prednisone immunosuppression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8782754" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Randomised controlled trial of steroid withdrawal in renal transplant recipients receiving triple immunosuppression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9380234" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : The impact of residual renal function on the adequacy of peritoneal dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22955228" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Independent of nephrectomy, weaning immunosuppression leads to late sensitization after kidney transplant failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21354453" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Human leukocyte antigen sensitization after transplant loss: timing of antibody detection and implications for prevention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24717218" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Prolonged immunosuppression preserves nonsensitization status after kidney transplant failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26529289" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Sensitization trends after renal allograft failure: the role of DQ eplet mismatches in becoming highly sensitized.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30236837" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Indications, risks and impact of failed allograft nephrectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17617860" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Nephrectomy after transplant failure: current practice and outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12913685" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Surgical complications of graft nephrectomy in the modern transplant era.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12629335" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Cumulative incidence, indications, morbidity and mortality of transplant nephrectomy and the most appropriate time for graft removal: only nonfunctioning transplants that cause intractable complications should be excised.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8671948" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : The management of the failed renal allograft.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8156119" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : New patterns of transplant nephrectomy in the cyclosporine era.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8126809" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Transplant nephrectomy over 20 years: factors involved in associated morbidity and mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Indications for nephrectomy of a failed transplant</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15340000" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Presence of a failed kidney transplant in patients who are on hemodialysis is associated with chronic inflammatory state and erythropoietin resistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15934958" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : At the peril of dialysis patients: ignoring the failed transplant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15934959" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : The management of the failed renal allograft: an enigma with potential consequences.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19875809" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Transplant nephrectomy improves survival following a failed renal allograft.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22974872" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Allograft nephrectomy: what is the best surgical technique?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27742346" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : A Single-center Experience of Allograft Nephrectomies Following Kidney Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25645777" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Review of a transplantectomy series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26036502" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Allograft nephrectomy: a single-institution, 10-year experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24157011" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Comparison of the clinical characteristics of renal transplant recipients who underwent early versus late graft nephrectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21470516" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Extracapsular versus intracapsular allograft nephrectomy: impact on allosensitization and surgical outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14612064" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : One center's experience with allograft nephrectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1733085" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : The influence of nephrectomy of the primary allograft on retransplant graft outcome in the cyclosporine era.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8664520" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Renal retransplants: effect of primary allograft nephrectomy on early function, acute rejection and outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12644168" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : The impact of allograft nephrectomy on percent panel reactive antibody and clinical outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20035868" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Detection of donor-specific HLA antibodies before and after removal of a rejected kidney transplant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22626959" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Donor-specific antibodies after ceasing immunosuppressive therapy, with or without an allograft nephrectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1354889" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Maintenance of in vivo tolerance by persistence of antigen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9184673" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Graft persistence effectively induces and maintains donor-specific unresponsiveness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9361966" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Pretransplant exposure to donor HLA-DR antigen in random transfusion units and the development of donor antigen-specific hyporeactivity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16112054" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Intolerance syndrome in failed renal allografts: incidence and efficacy of percutaneous embolization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11976736" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Percutaneous renal artery embolisation of non-functioning renal allografts with clinical intolerance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11982819" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Return to dialysis after renal transplantation. Which would be the best way?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24903392" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Initial vascular access type in patients with a failed renal transplant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25975965" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Hemodialysis Arteriovenous Vascular Access Creation After Kidney Transplant Failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16469763" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Comparison of peritoneal dialysis and haemodialysis after renal transplant failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21233457" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Impact of dialysis modality on survival after kidney transplant failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24084843" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Is dialysis modality a factor in the survival of patients initiating dialysis after kidney transplant failure?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16280374" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Effect of previously failed kidney transplantation on peritoneal dialysis outcomes in the Australian and New Zealand patient populations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17261432" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Survival on dialysis post-kidney transplant failure: results from the Scientific Registry of Transplant Recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12717218" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Decreased renal function is a strong risk factor for cardiovascular death after renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20628109" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Residual renal function in peritoneal dialysis after renal transplant failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19886330" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Predictors of residual renal function loss in peritoneal dialysis: is previous renal transplantation a risk factor?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26457605" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Waiting Time Between Failure of First Graft and Second Kidney Transplant and Graft and Patient Survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23503503" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Risks and benefits of preemptive second kidney transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16476722" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : The role of pre-emptive re-transplant in graft and recipient outcome.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
